Toll Free Helpline (India): 1800 1234 070

Rest of World: +91-9810852116

NAAS RATING: 5.23 | Free Publication Certificate
NAAS Rating: 5.23 new

Vol. 2, Issue 1 (2013)

Heart Failure Treatment In Patients With Recurrent Myocardial Infarction

Ruslana Denina
160 patients with heart failure classes II and III with recurrent myocardial infarction have undergone treatment by means of cardioprotector - isosorbide mononitrate – mononitrosid and metabolitotropic drug 5-lipoxygenase inhibitor corvitin/quercetin.  All the suggested treatment regimens of heart failure in patients with recurrent myocardial infarction had high antagonistic effectiveness, resulted in the decrease of blood pressure, pulse pressure, improved structural and functional characteristics of the myocardium (including the increase in ejection fraction (EF), and significant decrease of left ventricular end-diastolic dimension (LVEDd), end-diastolic volume (EDV), left ventricular mass index (LVMI), reduced NT-proBNP levels, Total NO and improved heart rate variability.
Pages: 30-35  |  1579 Views  37 Downloads

The Pharma Innovation Journal
How to cite this article:
Ruslana Denina. Heart Failure Treatment In Patients With Recurrent Myocardial Infarction. Pharma Innovation 2013;2(1):30-35.
Important Publications Links
The Pharma Innovation Journal

The Pharma Innovation Journal

Call for book chapter
The Pharma Innovation Journal